Customer-centric product presentations for monoclonal antibodies

AAPS Open

Review

Beate Bittner¹ 

[1] F. Hoffmann-La Roche Ltd., Global Product Strategy - Product Optimization, Grenzacher Strasse 124, CH-4070, Basel, Switzerland;

关键词: Customer centricity;    Parenteral;    Oral;    Subcutaneous;    Flexible care setting;    Product optimization;   

DOI  :  10.1186/s41120-022-00069-y

 received in 2022-09-21, accepted in 2022-12-02,  发布年份 2022

来源: Springer

【 摘 要 】

Delivering customer-centric product presentations for biotherapeutics, such as monoclonal antibodies (mAbs), represents a long-standing and paramount area of engagement for pharmaceutical scientists. Activities include improving experience with the dosing procedure, reducing drug administration-related expenditures, and ultimately shifting parenteral treatments outside of a controlled healthcare institutional setting. In times of increasingly cost-constrained markets and reinforced with the coronavirus pandemic, this discipline of “Product Optimization” in healthcare has gained momentum and changed from a nice-to-have into a must.This review summarizes latest trends in the healthcare ecosystem that inform key strategies for developing customer-centric products, including the availability of a wider array of sustainable drug delivery options and treatment management plans that support dosing in a flexible care setting. Three disease area archetypes with varying degree of implementation of customer-centric concepts are introduced to highlight relevant market differences and similarities. Namely, rheumatoid arthritis and inflammatory bowel disease, multiple sclerosis, and oncology have been chosen due to differences in the availability of subcutaneously dosed and ready-to-use self-administration products for mAb medicines and their follow-on biologics.Different launch scenarios are described from a manufacturer’s perspective highlighting the necessity of platform approaches. To unfold the full potential of customer-centric care, value-based healthcare provider reimbursement schemes that incentivize the efficiency of care need to be broadly implemented.

【 授权许可】

CC BY   
© The Author(s) 2023

【 图 表 】

Fig. 4

40798_2022_490_Article_IEq55.gif

40798_2022_490_Article_IEq52.gif